CD19 and congenital rubella syndrome: CD19-directed CAR-T has shown significant therapeutic efficacy for relapsed/refractory B-cell ALL with about 80% CR rates, however, 77% to 85% patients after CAR-T infusion would develop a unique treatment-related CRS with a wide constellation of symptoms with multiorgan involvement.[2,3] Although most cases of CRS are self-limited or controllable, some patients can exhibit severe to life-threatening CRS.